MedTrace Logo

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

NCT02180763 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2018-09-05

No results posted yet for this study

Summary

The purpose of this study is to compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL according to the delivery device.

Conditions

  • Primary Immunodeficiency (PID)

Interventions

BIOLOGICAL

Gammanorm

Sub-Q IgG

Sponsors & Collaborators

  • Octapharma

    lead INDUSTRY

Principal Investigators

  • Boris Bienvenu, MD · Universtiy Hospital of Caen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-08-28
Completion
2017-08-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02180763 on ClinicalTrials.gov